RANKL/RANK: from bone loss to the prevention of breast cancer

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
Denosumab 2 endocrinologydiseasesdrugs
calcitriol 1 endocrinologydiseasesdrugs
osteoporosis 7 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Denosumab 29892 of RANK-positive mammary luminal progenitor cells contributing to the development of mammary tumours. Denosumab : a way to prevent breast cancer?6.It is well recognized that particular environmental factors can modify
Denosumab 30773 blockade could be a feasible option for the prevention of breast cancer in BRCA1-mutation carriers. Denosumab , a monoclonal fully human RANKL-blocking antibody was initially developed for the treatment of osteoporosis.
calcitriol 12648 expression is also induced by parathyroid hormone, a central regulator of calcium homeostasis. Further, calcitriol (vitamin D3) has been shown to induce RANKL expression. Moreover, inflammatory cytokines secreted by
Select Disease Character Offset Disease Term Instance
osteoporosis 2707 reduced OPG and thus a relative rise of RANKL activity, ultimately leading to enhanced bone turnover and osteoporosis [[7],[8]]. Osteoporosis is a state of decreased bone mass with increased risks of fractures resulting
osteoporosis 2919 resulting in hospitalization and is one of the most frequent causes of death in the elderly. In women with osteoporosis , elevated RANKL plasma levels as well as increased plasma OPG levels and a higher OPG/RANKL ratio can
osteoporosis 3277 human monoclonal RANKL-blocking antibody denosumab has been developed and approved for the treatment of osteoporosis and skeletal related events in cancer [[10]], already benefiting tens of thousands of patients. Besides
osteoporosis 25616 underlying physiological or pathological conditions, e.g. RANKL or OPG serum levels do not correspond to osteoporosis . For instance, low serum RANKL levels are associated with a 10-fold higher risk of non-traumatic fractures
osteoporosis 30878 carriers.Denosumab, a monoclonal fully human RANKL-blocking antibody was initially developed for the treatment of osteoporosis . After successful completion of clinical trials, denosumab was approved for the treatment of postmenopausal
osteoporosis 30999 successful completion of clinical trials, denosumab was approved for the treatment of postmenopausal osteoporosis and the prevention of skeletal related events in patients with solid tumours [[10]]. To date, already
osteoporosis 32809 showed that, based on 11 000 patient years, low dose of denosumab (two injections per year, as used for osteoporosis ) are perfectly safe [[75]]. These results are very encouraging in terms of efficacy and safety and support

You must be authorized to submit a review.